Treatment of locally advanced @entity259 with combination @entity632 and XXXX .

@entity1 @entity632 @entity66 @entity5 @entity1161 @entity189 @entity259
Since 1979, 41 @entity1 with locally advanced @entity259 have been prospectively treated in our institution according to a combination regimen of low-dose @entity632 ( @entity632 ) and external-beam @entity1161 . Two types of treatment regimen were used depending on @entity5 histologic type. Group 1 @entity1 with well-differentiated papillary, follicular, or mixed @entity5 (n = 22) received the combined regimen consisting of once weekly administration of @entity632 (10 mg/m2) before @entity1161 ( @entity1161 ). Radiation therapy was carried out with a daily dose of 200 cGy for 5 days per week to a total @entity5 dose of 5600 cGy. Group 2 @entity1 with anaplastic giant and @entity189 of the thyroid (n = 19) received the combined regimen, consisting of once weekly administration of @entity632 (10 mg/m2) before hyperfractionated @entity1161 . Radiation therapy was carried out with a fractional dose of 160 cGy per treatment twice a day for 3 days per week to a total dose of 5760 cGy in 40 days. Initial complete @entity5 response rates in the group 1 and 2 were 91% and 84%, respectively. @entity5 control rates at 2 years after combined therapy were 77% and 68%, respectively. The median survival time was 4 years for group 1 and 1 year for group 2. There was no disproportionately enhanced normal tissue morbidity seen with this combined approach. @entity1 in group 1 have a good quality of life, once the @entity66 is under control due to the indolent course of the disease. On the contrary, most @entity1 in group 2 promptly developed distant metastases and died from the disease.
